Trial Profile
AZTEC: Open-label, prospective, single-arm, titrate-to-goal study evaluating the safety and efficacy of olmesartan medoxomil/amlodipine in patients with mild to moderate (Stage 1) and challenging (Stage 2) hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Jan 2013
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil/amlodipine (Primary)
- Indications Hypertension
- Focus Registrational; Therapeutic Use
- Acronyms AZTEC
- Sponsors Daewoong Pharmaceutical; Daiichi Sankyo Inc
- 25 May 2009 New trial record.